Wedbush Reaffirms Outperform Rating for Astria Therapeutics (NASDAQ:ATXS)

Astria Therapeutics (NASDAQ:ATXS)‘s stock had its “outperform” rating reissued by investment analysts at Wedbush in a report released on Friday, Benzinga reports. They presently have a $22.00 price objective on the biotechnology company’s stock. Wedbush’s target price suggests a potential upside of 127.04% from the stock’s current price.

Several other research firms have also recently commented on ATXS. HC Wainwright lowered their price target on shares of Astria Therapeutics from $18.00 to $16.00 and set a “buy” rating for the company in a report on Tuesday, April 23rd. Jefferies Financial Group boosted their price target on shares of Astria Therapeutics from $22.00 to $27.00 and gave the stock a “buy” rating in a report on Monday, March 25th.

Astria Therapeutics Stock Performance

Shares of Astria Therapeutics stock traded down $0.48 on Friday, reaching $9.69. The company had a trading volume of 215,389 shares, compared to its average volume of 957,561. The firm’s 50 day moving average price is $12.26 and its two-hundred day moving average price is $9.51. The firm has a market cap of $532.11 million, a PE ratio of -4.05 and a beta of 0.81. Astria Therapeutics has a 52-week low of $4.26 and a 52-week high of $16.90.

Astria Therapeutics (NASDAQ:ATXS) last released its quarterly earnings results on Monday, March 4th. The biotechnology company reported ($0.86) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.78) by ($0.08). As a group, sell-side analysts predict that Astria Therapeutics will post -1.55 EPS for the current year.

Institutional Trading of Astria Therapeutics

Institutional investors and hedge funds have recently bought and sold shares of the business. Vivo Capital LLC raised its position in Astria Therapeutics by 47.7% in the 4th quarter. Vivo Capital LLC now owns 2,482,727 shares of the biotechnology company’s stock valued at $19,067,000 after purchasing an additional 801,528 shares during the last quarter. Affinity Asset Advisors LLC grew its stake in shares of Astria Therapeutics by 53.7% during the 3rd quarter. Affinity Asset Advisors LLC now owns 1,000,300 shares of the biotechnology company’s stock worth $7,462,000 after purchasing an additional 349,425 shares during the period. Jump Financial LLC acquired a new position in shares of Astria Therapeutics during the 3rd quarter worth $111,000. AJOVista LLC acquired a new position in shares of Astria Therapeutics during the 4th quarter worth $51,000. Finally, Perceptive Advisors LLC grew its stake in shares of Astria Therapeutics by 82.9% during the 4th quarter. Perceptive Advisors LLC now owns 4,004,070 shares of the biotechnology company’s stock worth $30,751,000 after purchasing an additional 1,814,608 shares during the period. Hedge funds and other institutional investors own 98.98% of the company’s stock.

About Astria Therapeutics

Astria Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for allergic and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in Phase 1b/2 clinical trials for the treatment of hereditary angioedema.